Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death

Ophthalmology

Volumn 123, Issue 10, 2016, Pages 2225-2231

  Yashkin, Arseniy P ^a   Hahn, Paul ^b   Sloan, Frank A ^a  

^a DUKE UNIVERSITY   (United States)

^b NJRetina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; RANIBIZUMAB; VASCULOTROPIN A;

ACUTE HEART INFARCTION; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DRUG BIOAVAILABILITY; DRUG EFFECT; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CAUSE OF DEATH; CLINICAL TRIAL; INCIDENCE; MACULAR DEGENERATION; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE; SURVIVAL RATE; TIME FACTOR; TRENDS; UNITED STATES;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; MEDICARE; MYOCARDIAL INFARCTION; PROGNOSIS; RANIBIZUMAB; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; SURVIVAL RATE; TIME FACTORS; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84981715626     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2016.06.053     Document Type: Article

References (27)

1. 1 Skaat, A., Chetrit, A., Belkin, M., et al. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 153 (2012), 214–221.
2. 2 Bloch, S.B., Larsen, M., Munch, I.C., Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 153 (2012), 209–213.
3. 3 Sun, C., Klein, R., Wong, T.Y., Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study. Ophthalmology 116 (2009), 1913–1919.
4. 4 Hu, C.-C., Ho, J.-D., Lin, H.-C., Neovascular age-related macular degeneration and the risk of stroke a 5-year population-based follow-up study. Stroke 41 (2010), 613–617.
5. 5 Ikram, M.K., Mitchell, P., Klein, R., et al. Age-related macular degeneration and long-term risk of stroke subtypes. Stroke 43 (2012), 1681–1683.
6. 6 Pratt, N.L., Ramsay, E.N., Kemp, A., et al. Ranibizumab and risk of hospitalisation for ischaemic stroke and myocardial infarction in patients with age-related macular degeneration: a self-controlled case-series analysis. Drug Safety 37 (2014), 1021–1027.
7. 7 Schlenker, M.B., Thiruchelvam, D., Redelmeier, D.A., Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism. Am J Ophthalmol 160 (2015), 569–580.
8. 8 Avery, R.L., Gordon, G.M., Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema a systematic review and meta-analysis. JAMA Ophthalmol 134 (2016), 21–29.
9. 9 Taniguchi, H., Shiba, T., Maeno, T., Takahashi, M., Evaluation of carotid atherosclerosis, peripheral arterial disease, and chronic kidney disease in patients with exudative age-related macular degeneration without coronary artery disease or stroke. Ophthalmologica 233 (2015), 128–133.
10. 10 Curtis, L.H., Hammill, B.G., Schulman, K.A., Cousins, S.W., Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128 (2010), 1273–1279.
11. 11 Tunon, J., Maria Ruiz-Moreno, J., Luis Martin-Ventura, J., et al. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol 54 (2009), 339–348.
12. 12 Fernandez, A.B., Panza, G.A., Cramer, B., et al. Age-related macular degeneration and incident stroke: a systematic review and meta-analysis. PLoS One, 10, 2015, e0142968.
13. 13 Ng, W.Y., Tan, G.S.W., Ong, P.-G., et al. Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol 159 (2015), 557–564.
14. 14 Campbell, R.J., Bell, C.M., Paterson, J.M., et al. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis. Ophthalmology 119 (2012), 1604–1608.
15. 15 Kitchens, J.W., Do, D.V., Boyer, D.S., et al. Comprehensive review of ocular and systemic safety events with intravitreal aflibercept injection in randomized controlled trials. Ophthalmology 123 (2016), 1511–1520.
16. 16 French, D.D., Margo, C.E., Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study. Retina 31 (2011), 1036–1042.
17. 17 Ueta, T., Noda, Y., Toyama, T., et al. Systemic vascular safety of ranibizumab for age-related macular degeneration. Ophthalmology 121 (2014), 2193–2203.
18. 18 Schmidt-Erfurth, U., Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf 9 (2010), 149–165.
19. 19 Semeraro, F., Morescalchi, F., Duse, S., et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. Expert Opin Drug Saf 13 (2014), 785–802.
20. 20 Dedania, V.S., Bakri, S.J., Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. Curr Opin Ophthalmol 27 (2016), 224–243.
21. 21 Csaky, K., Do, D.V., Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 148 (2009), 647–656.
22. 22 Thulliez, M., Angoulvant, D., Le Lez, M.L., et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 132 (2014), 1317–1326.
23. 23 Duan, Y., Mo, J., Klein, R., et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 114 (2007), 732–737.
24. 24 Alexander, S.L., Linde-Zwirble, W.T., Werther, W., et al. Annual rates of arterial thromboembolic events in Medicare neovascular age-related macular degeneration patients. Ophthalmology 114 (2007), 2174–2178.
25. 25 Sloan, F.A., Hanrahan, B.W., The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration. JAMA Ophthalmol 132 (2014), 456–463.
26. 26 Stein, J.D., Hanrahan, B.W., Comer, G.M., Sloan, F.A., Diffusion of technologies for the care of older adults with exudative age-related macular degeneration. Am J Ophthalmol 155 (2013), 688–696.
27. 27 Chung, S.-D., Ho, J.-D., Hu, C.-C., et al. Increased risk of Parkinson disease following a diagnosis of neovascular age-related macular degeneration: a retrospective cohort study. Am J Ophthalmol 157 (2014), 464–469.